Clinical trials: Pseudobulbar Affect
Amyotrophic Lateral Sclerosis, Pseudobulbar Affect
Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect
The investigators aim to elucidate characteristics of structural and functional brain connectivity in patients with amyotrophic lateral sclerosis (ALS) and pseudobulbar affect (PBA) using diffusion kurtosis imaging (DKI) and…
- Trial name
- NCT06396260
- Testing
- Diffusion Kurtosis Imaging (DKI), Resting State Magnetoencephalography
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aalborg University Hospital
Amyotrophic Lateral Sclerosis
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
The purpose of this study is to compare and evaluate the safety of AVP-923 (dextromethorphan/quinidine) for the treatment of emotional lability in ALS patients.
- Trial name
- NCT00021697
- Testing
- AVP-923
- Where
- 17 sites in United States
- Volunteers
- 100 people
- Sponsor
- Avanir Pharmaceuticals
Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS)
PRISM Registry: Pseudobulbar Affect Registry Series
PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease
- Trial name
- NCT01366027
- Where
- United States
- Volunteers
- 5,290 people
- Sponsor
- Avanir Pharmaceuticals
Pseudobulbar Affect (Involuntary Laughing and/or Crying)
Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)
6 month study of NUEDEXTA ® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients.
- Trial name
- NCT02496039
- Testing
- NUEDEXTA®
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Avanir Pharmaceuticals
Pseudobulbar Affect (PBA), Stroke
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with…
- Conditions
- Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
- Trial name
- PRISM II (NCT01799941)
- Testing
- Nuedexta (DM 20 mg/Q 10 mg)
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Avanir Pharmaceuticals
Stroke, Emotionality
Piloting the Attention Training Technique for Post-Stroke Emotionalism
The aim of this mutli-phasic systematic case series is to explore if the Attention Training Technique (ATT) can improve symptoms of Post Stroke Emotionalism.
- Conditions
- Stroke, Emotionality, Pseudobulbar Affect, Lability Emotional
- Trial name
- NCT06457126
- Testing
- Attention Training Technique
- Where
- 2 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- University of Manchester
Alzheimer's Disease, Pseudobulbar Affect (PBA)
Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
The primary objective of this study is to test the hypothesis that Nuedexta (20/10) administered orally will reduce Pseudobulbar Affect (PBA) frequency and severity (CNS-Lability Scale and PLACS), with satisfactory safety and…
- Trial name
- NCT01832350
- Testing
- Nuedexta (20/10)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Multiple Sclerosis
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Pseudobulbar Affect is a condition characterized by frequent episodes of laughing and crying out of proportion. Other terms used to describe this condition include emotional lability, emotionalism, emotion incontinence, emotional…
- Trial name
- NCT00050232
- Testing
- AVP-923
- Where
- 20 sites in United States
- Volunteers
- 96 people
- Sponsor
- Avanir Pharmaceuticals
Pseudobulbar Affect (PBA)
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate [AVP-923-30] or 20…
- Trial name
- STAR (NCT00573443)
- Testing
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
- Where
- 62 sites in United States, Argentina and 1 more
- Volunteers
- 326 people
- Sponsor
- Avanir Pharmaceuticals
Alzheimer's Disease, Stroke
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).
- Conditions
- Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
- Trial name
- NCT00056524
- Testing
- AVP-923
- Where
- 39 sites in United States
- Volunteers
- 600 people
- Sponsor
- Avanir Pharmaceuticals